evt | Article | May 2012
One Question... What Are the Five Devices Your CLI Practice Can't Live Without?
With Sean P. Lyden, MD, FACS; Jos C. van den Berg, MD, PhD; Lawrence A. Garcia, MD, FACC, FAHA, FSCAI; Robert Lookstein, MD, FSIR, FAHA; Edward Y. Woo, MD; Mahmood Razavi, MD; Malcolm T. Foster III, MD, FACC; and John H. Rundback, MD
evt | Article | February 2015
On Purchasing Power, Cost Control, and Device Decisions
In response to the growing pressure to cut costs within hospitals, the Cleveland Clinic tasked vascular surgeon Sean P. Lyden, MD, to act as Medical Director of Supply Chain. He spoke with Endovascular Today about his responsibilities in this role, the forces affecting device innovation and education, and the Clinic's new group purchasing organization.
Sponsored by TriVascular, Inc.
evt | Article | September 2014 Supplement
evt | Article | September 2013 Supplement
Sponsored by Penumbra, Inc.
evt | Article | April 2020
Penumbra’s Complete Embolization Platform Now With Low-Profile Compatibility
With James F. Benenati, MD; Parag J. Patel, MD, MS, FSIR; Joel Raborn, MD; Andrew J. Gunn, MD; Justin P. McWilliams, MD; Fakhir Elmasri, MD; Sean P. Lyden, MD, FACS; Darren Schneider, MD; Kristina A. Giles, MD; and Frank R. Arko III, MD
evt | Article | March 2017
Ask the Experts: What Have You Learned From Long-Term Data Sets Beyond 10 Years, and How Will These Data Affect Your Practice?
Experts discuss key lessons from long-term EVAR studies and what they mean for the future.
With Sean P. Lyden, MD, FACS; Ian M. Loftus, MD, FRCS; Vincent Riambau, MD, PhD; Ramesh K. Tripathi, MD, FICS, FRCS, FACP, FRACS Vascular; and Mark A. Farber, MD
evt | Article | February 2015
Industry Consolidation's Potential Effects on Meetings and Physician Education
Endovascular Today asked for perspectives from leading conference organizers by posing the question, “To what degree are you concerned about how industry consolidation could affect support for vascular meetings and physician education?”
With Gary M. Ansel, MD; Barry T. Katzen, MD; Dierk Scheinert, MD; Roger M. Greenhalgh, MD; Sean P. Lyden, MD; and Frank J. Veith, MD
evt | News | November 1, 2016
ILLUMENATE Pivotal Trial Results Presented for Spectranetics' Stellarex Drug-Coated Balloon
November 2, 2016—The Spectranetics Corporation announced that the final 12-month results of the ILLUMENATE pivotal trial for the company’s Stellarex drug-coated balloon (DCB) were presented by Sean P. Lyden, MD, at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC. Dr. Lyden and Prakash Krishnan, MD, serve as coprincipal investigators of ILLUMENATE.
evt | News | June 17, 2011
Cook's Zilver PTX Compares Favorably to PTA for SFA Treatment in Diabetic Patients
June 18, 2011—The Society for Vascular Surgery (SVS) announced that results of a prospective, randomized trial indicate that the Zilver PTX paclitaxel-eluting stent (Cook Medical Group, Bloomington, IN) has sustained effectiveness compared to percutaneous transluminal angioplasty (PTA) in diabetic patients in the treatment of superficial femoral artery (SFA) lesions.
evt | News | September 12, 2017
PQ Bypass Reports Data on the Detour System for Percutaneous Treatment of Long-Segment Femoropopliteal Artery Disease
September 12, 2017—PQ Bypass announced that a subset analysis from the DETOUR I clinical trial investigated the safety and effectiveness results of the company's Detour System for treating long-segment (> 25 cm) blockages in the femoropopliteal artery.
evt | News | July 25, 2017
FDA Approves Spectranetics' Stellarex Drug-Coated Balloon
July 26, 2017—The Spectranetics Corporation announced receipt of US Food and Drug Administration premarket approval (PMA) of the Stellarex drug-coated balloon (DCB), which is designed to restore and maintain blood flow to the superficial femoral and popliteal arteries in patients with peripheral arterial disease (PAD).
evt | News | January 23, 2019
LINC 2019: Patient-Level Data Presentations at LINC Aim to Disprove Causality Between Paclitaxel and Increased Mortality
Attendees packed a special session to open LINC 2019 in Leipzig, Germany, to hear discussion of the recent meta-analysis published by Konstantinos Katsanos, MD, et al that suggested a link between the use of paclitaxel delivery devices and increased long-term mortality, as well as new data gathered by trialists and device manufacturers aiming to address these concerns.